Sensei Biotherapeutics (NASDAQ:SNSE) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101.
SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors.
The bad news for Sensei Biotherapeutics comes from its results in this trial. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn’t seem to be sitting well with SNSE stockholders today.
Dr. Shiraj Sen, a principal investigator in the SNS-101 study, said the following about the results:
“The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn’t expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors.”
SNSE Stock Market Movement on Friday
SNSE stock is seeing a decent amount of trading on Friday morning. This has more than 160,000 shares changing hands as of this writing. That’s closing in on its daily average trading volume of about 208,000 shares.
SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date (YTD) when markets closed yesterday.
Investors looking for more of the most recent stock market stories are in luck!
We have all of the hottest stock market news traders need to know about on Friday! That includes what’s going on with shares of Tharimmune (NASDAQ:THAR) stock, Netcapital (NASDAQ:NCPL) stock and Akanda (NASDAQ:AKAN) stock today. All of this info is good to go at the links below!
More Stock Market News for Friday
- Why Is Tharimmune (THAR) Stock Moving Today?
- Why Is Netcapital (NCPL) Stock Up 73% Today?
- Why Is Akanda (AKAN) Stock Up 133% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
